HETLIOZ Trademark

Trademark Overview

On Monday, April 1, 2019, a trademark application was filed for HETLIOZ with the United States Patent and Trademark Office. The USPTO has given the HETLIOZ trademark a serial number of 88366716. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 20, 2023. This trademark is owned by Vanda Pharmaceuticals Inc.. The HETLIOZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, containing tasimelteon, for use in the treatment of jet lag disorder; and pharmaceutical preparations containing tasimelteon for use in the treatment of autism spectrum disorders
hetlioz

General Information

Serial Number88366716
Word MarkHETLIOZ
Filing DateMonday, April 1, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 20, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 17, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations, containing tasimelteon, for use in the treatment of jet lag disorder; and pharmaceutical preparations containing tasimelteon for use in the treatment of autism spectrum disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 19, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameVanda Pharmaceuticals Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWashington, DC 20037
Party NameVanda Pharmaceuticals Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWashington, DC 20037

Trademark Events

Event DateEvent Description
Monday, March 20, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 20, 2023ABANDONMENT - NO USE STATEMENT FILED
Tuesday, August 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 8, 2022SOU EXTENSION 5 GRANTED
Thursday, July 14, 2022SOU EXTENSION 5 FILED
Thursday, July 14, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, December 29, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 27, 2021SOU EXTENSION 4 GRANTED
Monday, December 27, 2021SOU EXTENSION 4 FILED
Monday, December 27, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, July 6, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 2, 2021SOU EXTENSION 3 GRANTED
Friday, July 2, 2021SOU EXTENSION 3 FILED
Friday, July 2, 2021SOU TEAS EXTENSION RECEIVED
Saturday, June 5, 2021CORRECTED NOA E-MAILED
Friday, June 4, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 3, 2021SOU EXTENSION 2 GRANTED
Monday, January 25, 2021SOU EXTENSION 2 FILED
Thursday, June 3, 2021DIVISIONAL PROCESSING COMPLETE
Monday, January 25, 2021DIVISIONAL REQUEST RECEIVED
Tuesday, June 1, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, February 10, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, January 25, 2021TEAS REQUEST TO DIVIDE RECEIVED
Monday, January 25, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, October 20, 2020ASSIGNED TO EXAMINER
Saturday, July 18, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 16, 2020SOU EXTENSION 1 GRANTED
Thursday, July 16, 2020SOU EXTENSION 1 FILED
Thursday, July 16, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, February 11, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 17, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 17, 2019PUBLISHED FOR OPPOSITION
Wednesday, November 27, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 12, 2019ASSIGNED TO LIE
Wednesday, November 6, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 6, 2019EXAMINER'S AMENDMENT ENTERED
Wednesday, November 6, 2019NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, November 6, 2019EXAMINERS AMENDMENT E-MAILED
Wednesday, November 6, 2019EXAMINERS AMENDMENT -WRITTEN
Wednesday, June 12, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 12, 2019NON-FINAL ACTION E-MAILED
Wednesday, June 12, 2019NON-FINAL ACTION WRITTEN
Tuesday, June 11, 2019ASSIGNED TO EXAMINER
Friday, April 19, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 4, 2019NEW APPLICATION ENTERED

Related Keywords

hetlioz pharmaceutical tasimelteon treatment containing preparations disorders spectrum disorder autism